A novel specific pyrosequencing method for genotyping FCGR3A rs396991 without coamplification of homologous gene FCGR3B

Pharmacogenetics and Genomics

Volumn 23, Issue 11, 2013, Pages 631-635

  Van Der Straaten, Tahar ^a   Martijn, Richender ^a   El Hajoui, Toufik ^a   Baak Pablo, Renee ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

FCGR3A; FCGR3B; Genotyping; Pharmacogenetics; Pyrosequencing

Indexed keywords

PHENYLALANINE; VALINE;

ARTICLE; BINDING AFFINITY; FCGR3A GENE; FCGR3B GENE; GENE; GENE AMPLIFICATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; IMMUNE RESPONSE; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

GENOTYPE; GPI-LINKED PROTEINS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTORS, IGG; SEQUENCE ANALYSIS, DNA;

EID: 84886586679     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328365a4f2     Document Type: Article

References (12)

1. Bibeau F, Lopez-Crapez E, Di FF, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-1129.
2. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789-1796.
3. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947.
4. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758.
5. Kim JW, Kim JH, Im SA, Kim YJ, Han HS, Kim JS, et al. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology 2012; 83: 218-227.
6. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, et al. Analysis of Fcg receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 2012; 18: 3478-3486.
7. Park SJ, Hong YS, Lee JL, Ryu MH, Chang HM, Kim KP, et al. Genetic polymorphisms of FcgammaRIIa and FcgammaRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer. Oncology 2012; 82: 83-89.
8. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 2010; 70: 9554-9561.
9. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 2013; 6: 1.
10. Cooper N, Stasi R, Cunningham-Rundles S, Cesarman E, McFarland JG, Bussel JB. Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia. Br J Haematol 2012; 158: 539-547.
11. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de HM. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114.
12. Burchard PR, Malhotra S, Kaur P, Tsongalis GJ. Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay. Cancer Genet 2013; 206: 130-134.